Suppression of malignant glioma recurrence in a newly developed animal model by endogenous inhibitors

Lorenzo Bello, Carlo Giussani, Giorgio Carrabba, Mauro Pluderi, Valeria Lucini, Marilou Pannacci, Dario Caronzolo, Giustino Tomei, Roberto Villani, Francesco Scaglione, Rona S. Carroll, Andreas Bikfalvi

Research output: Contribution to journalArticlepeer-review


Glioma recurrences develop at the borders of the surgical cavity and are the main cause of their poor prognosis. There are no therapeutic advances to reduce the incidence of recurrence or animal models that closely mimic the clinical scenario to evaluate novel therapeutics. This work investigates the efficacy of endogenous inhibitors, in preventing the recurrence of human malignant gliomas, in a newly developed animal model of glioma surgical resection. We developed a nude mice model in which human glioma xenografts were microsurgically removed. After surgery, small islets of tumor cells persisted in the normal brain parenchyma, grew, and formed a recurrence. As inhibitors we used PEX and a fragment of platelet factor 4 (PF-4/CTF), which were administered systemically on a daily basis or in metronomic combination with chemotherapy for 120 days. Treatment was started 1 or 15 days after tumor removal. PEX or PF-4/CTF produced a significant improvement in survival, and delayed the appearance of glioma recurrence. Survival of animals that received daily PEX or PF-4/CTF was similar to that of animals that received metronomic PEX or PF-4/ CTF and chemotherapy, respectively. The effect of treatment was dependent on the time at which the treatment was initiated. The highest level of inhibition was observed when the treatment was administered 1 day after surgical resection and when PEX was used as the inhibitor (120 days versus 35 days of the control). Tumors treated with PEX or PF-4/CTF were small and well delineated, with few vessels. Postsurgical administration of PEX or PF-4/CTF significantly reduces the incidence human malignant glioma recurrences for a long period of time.

Original languageEnglish
Pages (from-to)3539-3548
Number of pages10
JournalClinical Cancer Research
Issue number11
Publication statusPublished - Nov 1 2002

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Suppression of malignant glioma recurrence in a newly developed animal model by endogenous inhibitors'. Together they form a unique fingerprint.

Cite this